Breaking News

Aptuit Verona Site Gets 100th Client

November 9, 2012

Clients include companies from EU, North America, Asia and South America

The Aptuit Center for Drug Discovery & Development in Verona, Italy has reached its 100th client, according to Stuart Needleman, president and chief operating officer of Aptuit LLC. The Verona facility, which Aptuit bought from GSK in mid-2010, provides drug discovery and development services to large, multinational pharmaceutical companies, mid-sized and small pharma companies, biotechs and startups.
Mark Hembarsky, vice president and site leader of the facility, said, "We are excited to have reached this important milestone of 100 clients at Aptuit Verona. In July of 2010, we started with one client, GlaxoSmithKline, following our acquisition of the site from them. Since that time, more and more clients have been recognizing that we have something unique and valuable to offer, and that we are certainly doing something right in helping them achieve their goals."
"Companies from the EU, North America, Asia and South America have placed projects with us covering numerous therapeutic areas," Mr. Hembarsky added. "We are proud that industry-leading companies like Pfizer, Chiesi Farmaceutici, Sunovion Pharmaceuticals, Boehringer Ingelheim, UCB, C10 Pharma, Autifony Therapeutics and GlaxoSmithKline, are among the clients that have chosen to partner with Aptuit."

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.